Cartesian licenses WestGene's in vivo CAR-T LNP platform for autoimmune diseases; MG trial starts 2H2026

Cartesian Therapeutics, Inc.

WestGene receives upfront payment and milestone-based payments; Cartesian gains exclusive rights to WestGene's tLNP platform for in vivo CAR-T.
Phase 1 dose-escalation study of Descartes-08 mRNA delivered via WestGene's tLNPs in generalized myasthenia gravis expected to begin 2H 2026.
In-human proof-of-concept data expected in 1H 2027; Cartesian plans to advance additional anti-BCMA CAR constructs and a BCMA TCE.
WestGene's prior clinical data showed no DLTs, SAEs, ICANS, or IRRs in up to 14 doses per patient; only Grade 1 CRS observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.